Please login to the form below

Not currently logged in

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

Pfizer launches online portal for UK pharmacists

Access Pfizer for Professionals will provide commercial, training and patient information to the pharma company's dispensing customers

Pfizer pharmacy dispensing doctor website

Pfizer has launched a new online portal to bolster its commercial offering to its dispensing customers in the UK.

In addition to account services and product information, Access Pfizer for Professionals will also give users access to training resources and support materials for patients, and comes online shortly before Pfizer's biggest-selling medicine the cholesterol-lowering drug Lipitor (atorvastatin) goes off-patent in May.

The website includes details of the company's entire portfolio of drugs, including its own range of generic products, which are, the company says, “backed by Pfizer's reputation for quality and safety”.

Pfizer said it hopes the new site will be used as a 'one-stop-shop' by pharmacists, dispensing doctors, validated buyers and professional body members.

Paul Wilson, Pfizer's commercial account director, said: “Access Pfizer for Professionals responds to pharmacists' feedback and offers a new, comprehensive resource that aims to support dispensing customers in their roles as business managers.

“The portal offers constant and immediate access to information relevant to our customers' commercial and professional needs – from key stock and account information to staff training, patient engagement resources and disease area data.”

The site's development was guided by the results of a survey of 200 pharmacists Pfizer carried out last year that showed the pharma company's customers wanted greater transparency of stock and supply information.

The survey also found that in terms of online account management, 50 per cent of respondents wanted the opportunity to sign up for commercial deals and 47 per cent wanted 24-hour access to their account.

According to the Pfizer survey, training needs were also high on pharmacists' agenda. Sixty nine per cent of those surveyed wanted to use the portal to register for professional service support and training.

The commercial section of the portal includes account information, discount statements, ordering history, price lists and deals, contract information, stock positions, product SPCs and PILs.

On the training side it features more than 20 Pfizer training workshops, CPD elements and therapy area-specific training modules – including on erectile dysfunction and cardiovascular disease.

The new Access Pfizer for Professionals portal will replace Pfizer's DTP website, which has been online since the company introduced DTP (direct-to-pharmacy) sales arrangements in the UK in 2007.

Pfizer's DTP arrangements saw it controversially decide to supply its medicines directly to pharmacists and pick just one distributor, Alliance Unichem, to handle the logistics of this.

In the process the company sparked an inquiry by the Office of Fair Trading about the deal, which concluded there was a significant risk DTP arrangements would result in higher costs to the NHS and could affect services to pharmacies and patients.

6th March 2012

From: Marketing


Featured jobs

Subscribe to our email news alerts


Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Drug pricing and competition
Strengthening business competition and reducing anti-competitive practices
How the CMA is tackling high prices for essential drugs...
APAC map
Pharmaceutical innovation in the APAC region
A first-of-its-kind study paints a vivid picture of the APAC region’s future...
Patient journey mapping: exploring the clinical and the emotional journey
By Chris Hodgson, Neil Rees, Sumira Riaz and Karen Petticrew While we can all agree that the value of developing a patient journey map cannot be underestimated when exploring the...